publication date: May. 17, 2019

Clinical Roundup

ASCO announces top studies to be presented at 2019 annual meeting

At a press briefing May 16, the American Society of Clinical Oncology announced the following studies will be presented at the 2019 ASCO Annual Meeting in Chicago:

A randomized clinical trial of nearly 49,000 postmenopausal women with no previous history of breast cancer found the women who followed a balanced, low-fat diet that included daily servings of fruits, vegetables, and grains had a 21% lower risk of dying from breast cancer than the women who followed their normal diet.

An interim analysis of the NCI-Children’s Oncology Group Pediatric Molecular Analysis for Therapy Choice trial found that 24% of screened patients with cancer that did not respond to treatment were eligible for treatment with a molecularly-targeted therapy—significantly more than projected prior to the study.

In a phase I/IB clinical trial, the targeted agent entrectinib resulted in complete or partial response in pediatric patients with central nervous system tumors and recurrent solid tumors harboring gene fusions involving the NTRK1/2/3, ROS1, or ALK genes.

A phase III randomized trial of 514 older and frail people with advanced gastroesophageal cancer found that regardless of age, frailty, or the ability to perform basic activities of daily living, patients given oxaliplatin (Eloxatin) and capecitabine (Xeloda) as palliative measures to keep the disease stable benefited as much from lower levels of the medicines, with less toxicity, as from higher levels.

A phase II/III randomized clinical trial shows that lenalidomide (Revlimid) significantly reduces the risk of smoldering multiple myeloma (a precancerous condition) from progressing to multiple myeloma among patients at moderate or high risk. At three years, in 91% of people with SMM receiving lenalidomide, the condition did not … Continue reading ASCO announces top studies to be presented at 2019 annual meeting

To access this members-only content, please log in.
Institutional subscribers, please log in with your IP.
If you're not a subscriber why not join today?
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.
Click here to join.

Copyright (c) 2020 The Cancer Letter Inc.